425 related articles for article (PubMed ID: 15834186)
21. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
Thike AA; Chng MJ; Fook-Chong S; Tan PH
Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
[TBL] [Abstract][Full Text] [Related]
23. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
24. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
25. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients.
Ikpatt OF; Ndoma-Egba R
Cent Afr J Med; 2003; 49(11-12):122-6. PubMed ID: 15301464
[TBL] [Abstract][Full Text] [Related]
26. Clinical impacts of histological subtyping primary breast cancer.
Fritz P; Klenk S; Goletz S; Gerteis A; Simon W; Brinkmann F; Heidemann E; Lütttgen E; Ott G; Alscher MD; Schwab M; Dippon J
Anticancer Res; 2010 Dec; 30(12):5137-44. PubMed ID: 21187502
[TBL] [Abstract][Full Text] [Related]
27. Angiogenesis and ER/PR status in primary breast cancer patients: an analysis of 158 needle core biopsies.
Vameşu S
Rom J Morphol Embryol; 2007; 48(1):25-31. PubMed ID: 17502947
[TBL] [Abstract][Full Text] [Related]
28. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR.
Green AR; Young P; Krivinskas S; Rakha EA; Claire Paish E; Powe DG; Ellis IO
Histopathology; 2009 Mar; 54(4):419-27. PubMed ID: 19309393
[TBL] [Abstract][Full Text] [Related]
29. E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma.
Wahed A; Connelly J; Reese T
Ann Diagn Pathol; 2002 Dec; 6(6):349-51. PubMed ID: 12478484
[TBL] [Abstract][Full Text] [Related]
30. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
Bird PA; Hill AG; Houssami N
Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of touch imprint cytology of core needle biopsy and section histopathology in breast cancer diagnosis].
Zhang ZH; Zhao LL; Guo HQ; Zheng S; Zhang BL; Xu XZ; Pan QJ; Zhang BN
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):921-6. PubMed ID: 21223801
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry.
van Agthoven T; Timmermans M; Foekens JA; Dorssers LC; Henzen-Logmans SC
Am J Pathol; 1994 Jun; 144(6):1238-46. PubMed ID: 7515559
[TBL] [Abstract][Full Text] [Related]
33. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
34. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
35. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
37. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
38. [Expression of ER, PR and cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance].
Wang ZB; Zhao P; Liu M; Li XH
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):514-7. PubMed ID: 15949328
[TBL] [Abstract][Full Text] [Related]
39. Clinical and biological characteristics of breast cancer.
Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
[TBL] [Abstract][Full Text] [Related]
40. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
